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Background: Although the treatment of Parkinson’s disease (PD) is very effective, in the course of the disease, 40%
to 60% of patients develop dyskinesias. The pathophysiology of dyskinesias is still unclear. Results of preclinical
research suggest that uptake and uncontrolled release of dopamine by serotonergic neurons is an important factor.
Based on this model, we hypothesized that dyskinesias will develop predominantly in PD patients with a relatively
preserved serotonergic system.
Methods: Between 1995 and 1998, 50 patients with early-stage untreated PD, diagnosed according to clinical
criteria, and reduced striatal [123I]β-carboxymethyoxy-3-beta-(4-iodophenyl) tropane (CIT) single-photon emission
computed tomography (SPECT) binding were recruited. To test our hypothesis, we retrospectively assessed baseline
[123I]β-CIT SPECT scans for striatal dopamine transporter (DAT) and midbrain serotonin transporter (SERT) availability
as well as the SERT-to-DAT ratios. We compared these data between patients that developed dyskinesias and
patients that did not develop dyskinesias during a mean follow-up of 14.2 years.
Results: Approximately half of the PD patients developed dyskinesias. No differences in baseline [123I]β-CIT DAT
availability, SERT availability, or SERT-to-DAT ratios were found between the dyskinetic and non-dyskinetic group.
The development of dyskinesias was most strongly associated with the age of onset (P = 0.002).
Conclusions: SERT-to-DAT ratios in early-stage untreated PD do not correlate with the future development of
dyskinesias. However, our study does not exclude the possibility that SERT-to-DAT ratios increase with disease
progression in patients that develop dyskinesias because of a slower rate of degeneration of the serotonergic
system.
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of onsetBackground
Parkinson’s disease (PD) is the second most common
form of neurodegenerative diseases [1]. A key neuro-
pathological characteristic of PD is a severe loss of
dopamine-producing neurons in the brainstem, which
induces several core motor features such as bradykinesia
and rigidity. The development of levodopa is a milestone
in the treatment of PD, since it is inexpensive and very
efficacious [2]. Levodopa is converted to dopamine* Correspondence: s.r.suwijn@amc.uva.nl
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in any medium, provided the original work is pwhich replenishes the stores of endogenous dopamine
and induces a fast and significant improvement in motor
function [3]. Due to disease progression, patients require
higher daily dosages of levodopa to produce a stable
clinical effect. Frequently, disabling side-effects in par-
ticular dyskinesias occur [4]. After 5 years of levodopa
treatment, approximately 30% to 40% of patients suffer
from dyskinesias, increasing to 40% to 60% after 10 years
of treatment [5,6]. Nevertheless, the pathophysiology
of dyskinesias is still unknown. There is a clear need
for a better understanding of the pathophysiology,
which may yield novel targets to develop improved
treatment strategies.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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substantia nigra to the striatum is the most prominent
dopaminergic pathway. The central serotonergic system
originates in the raphe nuclei. Within this nuclei com-
plex, the dorsal raphe nucleus projects predominantly to
cortical areas and the striatum [7]. PD is not only char-
acterized by dopaminergic degeneration but also by se-
rotonergic degeneration [8,9]. Preclinical research has
led to the development of a model that has the potential
to explain the development of dyskinesias [10]. This
model postulates that an imbalance between dopamine
and serotonin plays a crucial role in the development of
dyskinesias. More specifically, the model presumes that
in early stage PD, sufficient dopaminergic neurons exist
to regulate and release dopamine adequately. As the dis-
ease progresses, the number of dopaminergic neurons
declines. The loss of serotonin neurons, however, is rela-
tively mild compared to the loss of dopamine neurons
[8,11]. Terminal of serotonergic neurons in the striatum
can also take up, store, and release dopamine, yet these
neurons lack auto-regulatory feedback mechanisms of
dopaminergic neurons to release dopamine adequately
(serotonergic neurons lack D2 auto-receptors and dopa-
mine transporters) [12,13]. As a result of the lack of
these mechanisms, dopamine release from serotonin
nerve terminals in PD may be poorly regulated, resulting
in uncontrolled excessive swings in dopamine release
(called release of ‘false transmitter’).
In line with the model described above, studies in
dopamine-depleted rats and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated non-human primates have
shown that the removal of serotonin neurons and/or re-
duction of serotonin activity by serotonin agonists
resulted in a significant decrease of dyskinesias [10,14].
More specifically, the blockade of serotonin neuron ac-
tivity by the combination of 5-HT1A agonists prevented
the unregulated dopamine release by central serotoner-
gic neurons and consequently prevented the develop-
ment of dyskinesias in dopamine-depleted rats [15].
Furthermore, an increase in the incidence of dyskine-
sias has been observed in dopamine-depleted rats that
received a transplant containing relatively many sero-
tonin and few dopamine cells, whereas the dyskinesias
decreased when rats received a transplant consisting
predominantly of dopaminergic neurons [16]. An in-
crease of dyskinesias was also observed in two PD pa-
tients who received a graft with a high striatal serotonin/
dopamine transporter ratio. Moreover, administration of
a serotonin 1A receptor agonist (buspirone) significantly
reduced the severity of dyskinesias in both patients [17].
Hypothesis
All in all, particularly the results of the preclinical studies
suggest that dyskinesias may predominantly develop in PDpatients with a relative spared serotonergic system. This
study aims to determine whether an imbalance between the
loss of dopaminergic and serotonergic neurons precedes
the development of dyskinesias in PD. Therefore, we retro-
spectively assessed striatal dopamine transporter (DAT)
and midbrain serotonin transporter (SERT) availability as
well as the SERT-to-DAT ratios, as measured with [123I]
β-carboxymethyoxy-3-beta-(4-iodophenyl) tropane (CIT)
(a radiotracer that binds to both the DAT and SERT [18])
single-photon emission computed tomography (SPECT) in
drug-naïve early stage PD patients. We compared these
data between patients who had developed dyskinesias and
patients who had not developed dyskinesias during a mini-
mum of 5-year follow-up. We expected that PD patients
who had developed dyskinesias would have baseline [123I]
β-CIT SPECT scans with higher SERT-to-DAT ratios.Methods
Subjects
A total of 77 patients with early-stage untreated PD, di-
agnosed according to the United Kingdom Parkinson’s
Disease Society Brain Bank clinical diagnostic criteria
[19] and reduced striatal [123I]β-CIT SPECT binding at
the time of the initial clinical diagnosis were recruited
from the outpatient clinic for movement disorders at the
VU University Medical Center (VUMC) between 1995
and 1998. In all patients, [123I]β-CIT SPECT imaging
was performed before the initiation of dopaminomimetic
therapy. None of the subjects was using a compound
that potentially interferes with [123I]β-CIT SPECT bind-
ing. Furthermore, all medical records were reviewed to
ensure none of the patients was taking serotonergic
medication at the time of SPECT imaging. At the time
of diagnosis, the Beck Depression Inventory scale was
used to ensure none of the patients had signs of a major
depressive disorder. PD patients with dementia at base-
line were not included; a mini-mental state examination
score below 26 was used as an exclusion criterion. Dis-
ease duration was based on the dates of the clinical diag-
nosis by a neurologist and the last contact during
follow-up. The onset of dyskinesias was defined as the
first time the neurologist reported the presence of dyski-
nesias. All subjects gave written informed consent to the
research protocol, which was approved by the local me-
dical ethical committee of the VUMC. The ethical review
criteria conformed to the declaration of Helsinki.
In ten patients out of the total group of 77 patients,
the clinical diagnosis was changed during follow-up, as
previously reported [20], and these were excluded from
the present study (Figure 1). All patients were followed
for at least 5 years. Sixteen patients were lost to follow-
up, and 1 had an uncertain diagnosis, leaving a group of
50 patients for further analysis.
Further analysis (n=50)
[123I] -CIT SPECT imaging (n=77)
Assessed for eligibility and meeting 




Lost to follow-up (n=16)
Uncertain diagnosis (n=1)
No dyskinesias (n=27)Dyskinesias  (n=23)
Figure 1 Flow chart of patients’ disposition.
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SPECT imaging was performed using a brain-dedicated
system, the SME 810X system (Strichmann Medical
Equipment Inc., Medfield, MA, USA). This system con-
sists of 12 individual crystals each equipped with a fo-
cusing collimator. The spatial resolution of this camera
system is approximately 6.5 mm full-width at half-
maximum, throughout the 20-cm field of view. In order
to block the thyroid uptake of free radioactive iodine,
the subjects received potassium iodide orally. [123I]
β-CIT (specific activity >185 MBq/nmol, radiochemical
purity >99%) was injected intravenously at an approxi-
mate dose of 110 MBq. [123I]-labeling and acquisition
were performed as described previously [21]. Image
acquisition was performed 24 h after injection. Images
were corrected for attenuation and reconstructed in
3D [22,23].
Analysis of images
For the analysis of striatal and midbrain [123I]β-CIT
binding, two consecutive transverse slices representing
the most intense striatal and midbrain binding, were an-
alyzed. A standard anatomical region-of-interest (ROI)
template (constructed according to a stereotactic atlas)
and including regions for the caudate nucleus, puta-
men, whole striatum, midbrain, and occipital cortex
(representing non-specific binding) was placed bilaterally
on the images, as previously reported [24]. Estimates of
specific striatal binding were made by subtracting occipi-
tal counts from striatal counts. Specific [123I]β-CIT bin-
ding ratios in striatum, caudate nucleus, putamen, and
midbrain were calculated using the formula: (mean bin-
ding in ROI-mean occipital binding) / mean occipitalbinding. This formula is referred as binding potential
non-displaceable (BPND) [25].
Furthermore, to assess if a higher SERT-to-DAT ra-
tio precedes the development of dyskinesias, we cal-
culated the ratios of midbrain BPND versus BPND
assessed in the caudate nucleus, putamen, and whole
striatum. We also calculated these ratios in the most
affected side [17].
Statistical analysis
The Kolmogorov-Smirnov test was applied to screen for
normality. Group differences in the distribution of gen-
der, side-of-onset, and modified Hoehn and Yahr scores
were analyzed by means of the chi-square test. Analysis
with regard to group difference in time from diagnosis
until start of levodopa was analyzed using the Mann–
Whitney U test. Possible differences in age, age of onset,
disease duration, time between start of levodopa and the
development of dyskinesias, years of levodopa use, and
the unified Parkinson’s disease rating scale (UPDRS)
motor scores were analyzed using the independent t test.
In addition, the UPDRS motor score was divided into
two subscores that represented predominantly dopamin-
ergic (subscore A) and non-dopaminergic (subscore B)
deficiency [26]. We compared the [123I]β-CIT BPND
values and SERT-to-DAT ratios between the group with
dyskinesias (PDDYS) and without dyskinesias (PDNDYS)
using one-way analysis of variance. After transformation
by means of a natural logarithm, all met with the as-
sumption of normality. We intended to perform logistic
regression to assess the impact of the different variables
on the chance of developing dyskinesias. Considering
that the smallest group consisted of 23 patients, only 2
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we used the independent t test to analyze the variables
independently. All analyzes were performed at a signifi-
cance level of 0.05 (two-tailed). Analysis was done
using the SPSS 20.0 software package (IBM SPSS Inc.,
Chicago, IL, USA).Results
Patients
The demographic and clinical characteristics are listed
in Table 1. Twenty-three patients (46%) developed dyski-
nesias, and 27 (54%) did not. Twelve patients died dur-
ing follow-up (ten in PDNDYS and two in the PDDYS
group). The mean follow-up of the deceased patients
was 11.8 years age of onset (P = 0.002), disease duration
(P = 0.003), UPDRS motor score at the moment of im-
aging (P = 0.008), the total follow-up period (P = 0.004),
and years of levodopa use (P < 0.001), were signifi-
cantly different between the PDDYS and PDNDYS
groups. There were no differences regarding the other






Age of onset PD (mean ± SD)
(year)
56.8 ± 6.8 49.7 ± 10.9 0.002
Male sex number (percent) 15 (56) 16 (70) 0.39
Total follow-up (mean ± SD)
(months)
155 ± 49 190 ± 29 0.004
Most affected side (striatal)
(right/left)
11/16 11/12 0.43
Disease duration (mean ± SD)
(year)
12.8 ± 4.1 15.8 ± 2.4 0.003
Disease duration until levodopa
use (median, ICR) (year)
3.0, 4.75 2.4, 2.6 0.57
Disease duration until onset
dyskinesias (mean ± SD) (year)
NA 7.8 ± 3.9 NA
Levodopa use until onset
dyskinesias (mean ± SD) (year)
NA 5.1 ± 3.0 NA
Levodopa use (mean ± SD) (year) 9.5 ± 3.4 13.2 ± 2.0 <0.001
UPDRS motor score at moment
of imaging
16.9 ± 6.4 21.4 ± 5.1 0.008
(total range, 0 to 108) (mean ± SD)
Subscore A (0 to 88) 10.8 ± 3.4 14.2 ± 3.4 0.001
Subscore B (0 to 20) 6.1 ± 3.9 7.2 ± 2.8 0.25
Modified HY score at moment of
imaging (1/1.5/2/2.5)
7/3/8/9 6/1/9/7 0.79
PD Parkinson’s disease, PDNDYS PD patients subgroup that did not develop
dyskinesias, PDDYS PD patients subgroup that did develop dyskinesias, SD
standard deviation, ICR interquartile range, NA data not available, UPDRS
unified Parkinson’s disease rating scale, UPDRS subscore A, consists of
dopaminergic symptoms, subscore B, consists of non-dopaminergic symptoms,
HY Hoehn and Yahr.Analysis of [123I]β-CIT SPECT binding
The mean [123I]β-CIT BPND in the putamen was reduced
compared to the caudate nucleus, the typical pattern of
degeneration in PD. In the whole group, BPND in the mid-
brain correlated significantly (Pearson’s correlation) with
BPND in the most affected putamen (r = 0.496, P < 0.001)
and whole striatum (r = 0.532, P < 0.001; Figure 2).
No differences in baseline [123I]β-CIT BPND were
found between the PDDYS and PDNDYS group (Table 2).
This was true for BPND in the caudate nucleus, putamen,
whole striatum (mean for both sides, as well as for the
most affected side), and in the midbrain. Also, no signifi-
cant differences between PDNDYS and PDDYS in SERT-
to-DAT ratios were observed (Table 2). Also, BPND in
the caudate nucleus, putamen, striatum, and midbrain
did not predict the development of dyskinesias.
Discussion
This is the first study to assess SERT-to-DAT ratios in a
relatively large cohort of drug-naive patients with early
stage PD and a mean follow-up of 14 years. During a
mean follow-up of 14 years, 46% of our patients devel-
oped dyskinesias, which is in accordance with the
existing literature [5,6]. Patients in the PDDYS group had
longer mean disease duration and consequently had lon-
ger follow-up than patients in the PDNDYS group. This
could be explained by the uneven distribution of de-
ceased patients (ten in the PDNDYS and two in PDDYS
group) and the lower age of onset in the PDDYS group.
Also, at the moment of imaging, patients in the PDDYS
group had higher UPDRS motor scores than patients in
the PDNDYS group. The difference in UPDRS scores was
caused by a difference in dopaminergic rather than non-
dopaminergic symptoms (Table 2). Interestingly, this
subgroup of patients was younger at disease onset, so
one can speculate that younger patients often still work
and have busy lives and therefore may not notice the
subtle motor signs of PD.
Our study confirms that the age of onset of disease is
an independent risk factor for developing dyskinesias.
The two groups had a mean age of PD onset of 57
(PDNDYS) and 50 years (PDDYS), respectively. This obser-
vation is in line with previous reports, which showed
that the 5-year incidence of dyskinesias in newly diag-
nosed PD patients is age of onset-dependent: 50% be-
tween the ages of 40 and 59 years, 26% between the ages
of 60 and 69 years, and 16% at 70 years and older [6].
Furthermore, our patients who developed dyskinesias
started on average of 0.6 years earlier with levodopa
compared to the PDNDYS group (3.0 and 2.4 years, re-
spectively) due to the longer disease duration, hence the
difference in duration of levodopa use.
The hypothesis is that serotonergic neurons lack the
feedback mechanisms of dopaminergic neurons to
Figure 2 Correlation between serotonin and dopamine transporter binding. Serotonin transporter binding (BPND midbrain) is significantly
correlated with dopamine transporter binding in the most affected putamen (BPND putamen most affected side, left panel; r = 0.496, P ≤ 0.001)
and striatum (BPND striatum, right panel; r = 0.532, P ≤ 0.001).
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dopamine release from serotonin nerve terminals will be
poorly regulated, resulting in uncontrolled, excessive
swings in dopamine release. In contrast to this hypoth-
esis, in the present study, the dyskinesias were not pre-
ceded by a higher SERT-to-DAT ratio in patients with
dyskinesias compared to non-dyskinetic patients. Our
findings, however, do not necessarily reject theTable 2 Mean specific to non-specific [123I]β-CIT binding
ratios (BPND) (mean ± SD) and SERT-to-DAT ratios





Striatum, whole 4.02 ± 0.30 4.16 ± 0.24 0.66
Striatum, most affected side 3.43 ± 0.31 3.59 ± 0.27 0.57
Caudate nucleus, whole 6.02 ± 0.30 6.33 ± 0.25 0.52
Caudate nucleus, most affected side 5.34 ± 0.34 5.73 ± 0.28 0.43
Putamen, whole 3.03 ± 0.32 3.00 ± 0.26 0.93
Putamen, most affected side 2.39 ± 0.33 2.43 ± 0.28 0.82
Midbrain 1.05 ± 0.40 1.14 ± 0.35 0.41
Midbrain/Putamen, whole 0.33 ± 0.32 0.35 ± 0.36 0.48
Midbrain/Putamen most
affected side
0.42 ± 0.32 0.44 ± 0.38 0.67
Midbrain/Caudate, whole 0.17 ± 0.32 0.17 ± 0.32 0.88
Midbrain/Caudate, most
affected side
0.19 ± 0.34 0.19 ± 0.37 0.97
Midbrain/Striatum, whole 0.25 ± 0.31 0.26 ± 0.34 0.75
Midbrain/Striatum, most
affected side
0.29 ± 0.31 0.30 ± 0.38 0.87
SERT serotonin transporter, DAT dopamine transporter, SD standard deviation,
PD Parkinson’s disease, PDNDYS PD patients subgroup that did not develop
dyskinesias, PDDYS PD patients subgroup that developed dyskinesias.hypothesis that dyskinesias are associated with a rela-
tively preserved serotonergic system. More specifically,
since we performed a [123I]β-CIT scan at baseline, we
cannot exclude the possibility that a change in SERT-to
-DAT ratio occurs later in the course of the disease as a
result of a slower progression of the degeneration of the
serotonergic system compared to that of the dopamin-
ergic system, particularly in patients that go on to de-
velop dyskinesias. In this regard, it is of interest that a
recent study using positron emission tomography (PET)
and the selective SERT tracer [11C]labeled 3-amino-4-(2-
dimethylaminomethyl-phenylsulfanyl)benzonitrile (DASB)
demonstrated a non-linear loss of presynaptic serotoner-
gic neurons across the clinical course of PD. In the early
stages of PD (disease duration shorter than 5 years), [11C]
DASB uptake was reduced only in the caudate nucleus,
hypothalamus, thalamus, and anterior cingulate cortex. In
established PD (disease duration 5 to 10 years), the uptake
was additionally reduced in the putamen, insular cor-
tex, prefrontal cortex, and posterior cingulate cortex
[27]. Furthermore, in other studies, loss of dopamin-
ergic input to the putamen was severely reduced in
early PD stages, while the loss of [11C]DASB uptake in
the putamen occurred later [28,29]. These data are in
support of the assumption that serotonergic degene-
ration occurs at a different/slower rate in patients who
develop dyskinesias compared to patients that do not.
DAT binding in PD is commonly asymmetric, and the
loss of binding is generally more profound in the puta-
men than in the caudate nucleus, which is also the case
in this study, thus confirming the findings of earlier
DAT SPECT studies in PD [20,23]. We hypothesized
that if dopamine would be taken up predominantly by
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occur in the most affected striatal area. In other words,
if high SERT-to-DAT ratios precede the development of
dyskinesias, one may postulate that SERT-to-DAT ratios
will be highest in the most affected putamen. However,
also in this part of the striatum, SERT-to-DAT ratio was
almost similar (Table 2) between the two groups.
Although it is not possible to measure SERT availa-
bility in the striatum using [123I]β-CIT, midbrain [123I]
β-CIT binding is mainly associated with the binding to
SERT, while binding in the striatum is mainly associated
with binding to DAT [24]. Therefore, DAT and SERT
availability can be measured accurately with [123I]β-CIT
SPECT in different areas of the brain. However, in the
present study, SERT binding in the midbrain correlated
significantly with DAT binding in the most affected pu-
tamen and whole striatum (Figure 2). This finding is in
line with a previous PET study which reported a positive
correlation between DAT and SERT binding in the stri-
atum of PD patients [30]. Although such a positive cor-
relation could not be replicated in a later smaller study
[31], this might indicate that SERT expression in the
midbrain and striatum are associated. Unfortunately, in
the period in which the participants were recruited and
imaged, selective SERT tracers for SPECT, like [123I]
ADAM, were not available to assess SERT binding in the
striatum [32]. On the other hand, both [123I]FP-CIT and
[123I]β-CIT have been used to image SERT and DAT in
different brain areas [23,33], though the DAT/SERT se-
lectivity is somewhat lower for β-CIT (1.7:1 and 2.8:1,
respectively), which favors the use of [123I]β-CIT over
[123I]FP-CIT to assess extrastriatal SERT binding [34].
Our study has both strengths and limitations. Patients
were screened to exclude the presence of major depres-
sive disorders that might have had a possible con-
founding effect. Furthermore, we reviewed the medical
charts, with the current knowledge, to determine
whether any of the patients was using a compound that
may have interfered with [123I]β-CIT binding at the time
of diagnosis. Moreover, all scans were acquired before
any dopaminergic medication was initiated to reduce
possible confounding effects.
Due to the small group size (n = 23) an accurate ana-
lysis using logistic regression to assess the impact of
other variables (limited to two covariates) was not pos-
sible. However, the BPND in striatal and midbrain areas
were not even close to a significant difference between
groups (Table 2). Therefore, it is unlikely that a larger
prospective study would prove that the SERT-to-DAT
ratio in early stage drug-naïve PD patients correlates with
the development of dyskinesias. Another potential limita-
tion of this study is the retrospective collection of dyskin-
esia data and the accompanying disadvantages thereof.
However, most of the patients were closely monitored.Conclusions
In conclusion, we found that the development of dyski-
nesias is not associated with baseline striatal DAT, mid-
brain SERT availability, or higher SERT-to-DAT ratios.
In addition, we confirmed that development of dyskine-
sias is age-of-onset-dependent. The first finding does not
support preclinical data suggesting an influence of rela-
tive sparing of the serotonergic system. However, we
cannot exclude that the progression of degeneration of
the serotonergic system is slower in PDDYS compared to
PDNDYS, ultimately resulting in higher SERT-to-DAT ra-
tios at the onset of dyskinesias. Prospective imaging
studies, using selective radiotracers for the SERT and
DAT, are needed to shed more light on the presumed
role of a relatively preserved serotonergic system in the
induction of dyskinesias.
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